Copied
 
 
Formål
HistorikStartStop
Selskabets formål er at udvikle og sælge behandlinger til øjensygdomme og hermed forbundet virksomhed10.09.201525.09.2020
Virksomheden har ikke ændret Formål i sin levetid.
Ingen nuværende registrering.
Status
HistorikStartStop
OPLØST EFTER FRIVILLIG LIKVIDATION25.09.202025.09.2020
UNDER FRIVILLIG LIKVIDATION22.11.201924.09.2020
NORMAL08.11.201721.11.2019
UNDER TVANGSOPLØSNING31.08.201707.11.2017
NORMAL10.09.201530.08.2017
Ingen nuværende registrering.
Branche
HistorikStartStop
Anden teknisk rådgivning (711290)04.10.201725.09.2020
Uoplyst (999999)10.09.201503.10.2017
Ingen nuværende registrering.
Revision
HistorikStartStop
false30.08.201825.09.2020
true10.09.201529.08.2018
Ingen nuværende registrering.
Revisor
HistorikStartStop
inforevision statsautoriseret revisionsaktieselskab30.08.201825.09.2020
Virksomheden har ikke ændret Revisor i sin levetid.
Ingen nuværende registrering.
Form
HistorikStartStop
8110.09.201525.09.2020
Virksomheden har ikke ændret Form i sin levetid.
Ingen nuværende registrering.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
HistorikStartStop
2425626604.10.201725.04.2018
Virksomheden har ikke ændret Telefon i sin levetid.
Ingen nuværende registrering.
Navne
Ingen nuværende registrering.
Binavne
HistorikStartStop
RetiCare IVS25.04.201825.09.2020
RetiCare 10/09/15 IVS10.09.201525.09.2020
Ingen nuværende registrering.
Tegningsregel
HistorikStartStop
Virksomheden tegnes af en likvidator22.11.201925.09.2020
Selskabet tegnes af tre bestyrelsesmedlemmer eller af Selskabets administrerende direktør og bestyrelsesformanden i forening25.04.201821.11.2019
Selskabet tegnes af direktionen i forening04.10.201724.04.2018
Selskabet tegnes af direktionen i forening10.09.201531.08.2017
Ingen nuværende registrering.
Ansatte
23.07.2024
Kapital
23.07.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):Basis for opinionWe conducted our audit in accordance with international Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the “Auditor’s Responsibilities for the Audit of the Financial Statements” section of our report. We are independent of the company in accordance with the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):OpinionWe have audited the financial statements of RetiPharma IVS for the financial year 1 January to 31 December 2018, which comprise the accounting policies applied, the income statement, the balance sheet, statement of changes in equity and notes. The financial statements are prepared in accordance under the Danish Financial Statements Act. &nbspIn our opinion the financial statement give a true and fair view of the Companys financial position at 31 December 2018, and of the result of the Companys operations for the financial year 1 January to 31 December 2018 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Statement on the Management’s reviewManagement is responsible for Management’s Review. &nbspOur opinion on the Financial Statements døs not cover Management’s Review, and we do not express any form of assurance conclusion thereon. &nbspIn connection with our audit of the Financial Statements, our responsibility is to read Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the Financial Statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated. &nbspMoreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financial Statements Act. &nbspBased on the work we have performed, we conclude that Management’s Review is in accordance with the Financial Statements and has been prepared in accordance with the requirements of the Danish Financial Statement Acts. We did not identify any material misstatement of Management’s Review.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
23.07.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
23.07.2024
Ingen nuværende registrering.
Ingen historik.